A Phase III, Parallel Group, Prospective, Randomized, Double-blind, Active-controlled, Two-arm, Multi-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of MVC-COV1901 Compared to AZD1222 in Adults of 18 Years and Above
Latest Information Update: 24 Nov 2022
At a glance
- Drugs MVC COV1901 (Primary) ; AZD 1222
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Medigen Vaccine Biologics
- 17 Nov 2022 Interim results assessing Safety and immunogenicity data of MVC-COV1901 from the study in Paraguay published in the Vaccine
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 23 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.